Drug delivery company Aviron sold for $1.5 billion
This article was originally published in Clinica
Executive Summary
Drug delivery company Aviron is to be bought by biotechnology company MedImmune in an exchange offer and merger transaction valued at around $1.5 billion. Aviron's key product is FluMist, an intranasal flu vaccine that has not yet got FDA clearance.